Managing Community-Acquired Pneumonia with Glucocorticoids in Resource-Limited Settings
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on January 12th, 2026
|
Previous studies had found that glucocorticoids can help reduce the inflammation in patients with community-acquired pneumonia. However, most of these studies were conducted in well-resourced settings and excluded chronic disease commonly found in limited resource settings such as HIV and tuberculosis. With funding from the Wellcome Trust, a study was conducted to assess the usage of glucocorticoids in treating community-acquired pneumonia in a limited resource setting.
The clinical study was conducted in Kenya, and it included 2180 participants who had been hospitalized and diagnosed with community-acquired pneumonia. At admission 37% of the participants had an oxygen saturation level of less than 90%, and around 4% experienced severe dyspnea with a respiratory rate above 30 breaths per minute. Approximately 15% of the patients were HIV-positive, and around 2% experienced pulmonary tuberculosis.
The patients were randomly assigned to be treated with either standard care or with low-dose glucocorticoids for 10 days. After 30 days, the researchers found that glucocorticoid reduced the risk of death by 16%, which is consistent with previous studies performed in different settings. Glucocorticoid usage is associated with a higher risk of reversible hyperglycemia; thus, the researchers recommended frequent blood glucose monitoring during the course of treatment.
The clinical study was conducted in Kenya, and it included 2180 participants who had been hospitalized and diagnosed with community-acquired pneumonia. At admission 37% of the participants had an oxygen saturation level of less than 90%, and around 4% experienced severe dyspnea with a respiratory rate above 30 breaths per minute. Approximately 15% of the patients were HIV-positive, and around 2% experienced pulmonary tuberculosis.
The patients were randomly assigned to be treated with either standard care or with low-dose glucocorticoids for 10 days. After 30 days, the researchers found that glucocorticoid reduced the risk of death by 16%, which is consistent with previous studies performed in different settings. Glucocorticoid usage is associated with a higher risk of reversible hyperglycemia; thus, the researchers recommended frequent blood glucose monitoring during the course of treatment.